|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122095 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-09 09:06:26 |
|
注册时间: Date of Registration: |
2026-04-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
胃癌细胞通过调控B细胞生发中心活性重塑淋巴结内免疫微环境的机制研究 |
|
Public title: |
Study on the Mechanism by which Gastric Cancer Cells Remodel the Immune Microenvironment within Lymph Nodes by Regulating B Cell Germinal Center Activity |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
胃癌细胞通过调控B细胞生发中心活性重塑淋巴结内免疫微环境的机制研究 |
|
Scientific title: |
Study on the Mechanism by which Gastric Cancer Cells Remodel the Immune Microenvironment within Lymph Nodes by Regulating B Cell Germinal Center Activity |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘鹏程 |
研究负责人: |
胡承恩 |
|
Applicant: |
Pengcheng Liu |
Study leader: |
Chengen Hu |
|
申请注册联系人电话: Applicant telephone: |
+86 176 6045 2010 |
研究负责人电话:
Study leader's |
+86 176 6045 2010 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
pengcheng0112@126.com |
研究负责人电子邮件: Study leader's E-mail: |
stevenhu76@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区乌鲁木齐中路12号复旦大学附属华山医院普外科胃肠外科中心 |
研究负责人通讯地址: |
上海市静安区乌鲁木齐中路12号复旦大学附属华山医院普外科胃肠外科中心 |
|
Applicant address: |
Fudan University Affiliated Huashan Hospital, Department of General Surgery, Gastrointestinal Surgery Center, No. 12 Urumqi Middle Road, Jing'an District, Shanghai |
Study leader's address: |
Fudan University Affiliated Huashan Hospital, Department of General Surgery, Gastrointestinal Surgery Center, No. 12 Urumqi Middle Road, Jing'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属华山医院 |
||
|
Applicant's institution: |
Fudan University Affiliated Huashan Hospital |
||
|
研究负责人所在单位: |
复旦大学附属华山医院 |
||
|
Affiliation of the Leader: |
Fudan University Affiliated Huashan Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2026)临审第(740)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属华山医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee of Huashan Hospital Affiliated to Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-02 00:00:00 | ||
|
伦理委员会联系人: |
吴翠云 |
||
|
Contact Name of the ethic committee: |
Cuiyun Wu |
||
|
伦理委员会联系地址: |
上海市乌鲁木齐中路12号 |
||
|
Contact Address of the ethic committee: |
No. 12 Urumqi Middle Road, Jing'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 176 6045 2010 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属华山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fudan University Affiliated Huashan Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市乌鲁木齐中路12号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 12 Urumqi Middle Road, Jing'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京白求恩公益基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Bethune Charity Foundation |
||||||||||||||||||||||
|
研究疾病: |
胃癌 |
||||||||||||||||||||||
|
Target disease: |
Gastric Cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
明确胃癌细胞重塑B细胞生发中心的关键调控因子SEMA4G在转移淋巴结免疫微环境重塑过程中的具体作用及其机制,揭示高侵袭性胃癌细胞先重塑淋巴结免疫微环境,再转移至淋巴结定植的完整通路。 |
||||||||||||||||||||||
|
Objectives of Study: |
Clarify the specific role and mechanism of the key regulatory factor SEMA4G, which remodels B cell germinal centers in gastric cancer cells, in the process of remodeling the immune microenvironment of metastatic lymph nodes, and reveal the complete pathway by which highly invasive gastric cancer cells first remodel the lymph node immune microenvironment and then metastasize to and colonize the lymph nodes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄50-70岁,无已知的严重器质性疾病。 (2)经病理确诊为胃恶性肿瘤,男女不限。 (3)术后病理证实有淋巴结转移。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age 50-70 years, with no known severe organic diseases. 2. Pathologically confirmed malignant gastric tumor, regardless of gender. 3. Postoperative pathology confirms lymph node metastasis. |
||||||||||||||||||||||
|
排除标准: |
(1)有吞咽困难、上消化道出血症状者; (2)存在食管-胃底静脉曲张、食管狭窄者; (3)既往胃部外科手术史者; (4)存在凝血功能障碍或需持续服用抗凝药、抗血小板药物者; (5)存在胃镜检查和黏膜活检禁忌症者; (6)本人拒绝配合研究方案及拒绝签署知情同意书。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those with difficulty swallowing or symptoms of upper gastrointestinal bleeding; 2. Those with esophageal-gastric varices or esophageal strictures; 3. Those with a history of gastric surgery; 4. Those with coagulation disorders or who need to continuously take anticoagulant or antiplatelet drugs; 5. Those who have contraindications for gastroscopy and mucosal biopsy; 6. Individuals who refuse to cooperate with the research protocol and refuse to sign the informed consent form. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |